Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Journal Guam.
Press releases published on July 9, 2025
Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity
GlobeNewswire
·
July 9, 2025
-- Bivamelagon achieved BMI reductions in patients with acquired hypothalamic obesity of -9.3% and -7.7% in 600mg and 400mg cohorts, respectively, at 14 weeks -- -- Post-hoc analysis showed BMI reductions in bivamelagon trial were consistent with BMI …
Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium
GlobeNewswire
·
July 9, 2025
SOLANA BEACH, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, …
Atsena Therapeutics Announces Alignment with FDA on Regulatory Pathway to Approval for ATSN-201 in X-Linked Retinoschisis (XLRS)
GlobeNewswire
·
July 9, 2025
Outcome of Regenerative Medicine Advanced Therapy (RMAT) meeting provides clear regulatory pathway to approval in a continuous Phase 1 / 2 / 3 study, avoiding the requirement for an additional registrational study and accelerating time to potential …
BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study
GlobeNewswire
·
July 9, 2025
[IMAGES BELOW] Complete resolution maintained at 6 months in first patient treated with BriaCell’s Bria-OTS in Phase 1/2a study No treatment limited toxicities observed Patient remains on study with stable disease elsewhere PHILADELPHIA and VANCOUVER, …
Theratechnologies Reports Financial Results for the Second Quarter 2025
GlobeNewswire
·
July 9, 2025
Q2 2025 total revenue of $17.7 million, and $36.8 million for the first six months of Fiscal 2025 Positive Adjusted EBITDA1 for the fifth straight quarter Subsequent to quarter end, Theratechnologies entered into a definitive agreement to be acquired by an …
Theratechnologies présente ses résultats financiers pour le deuxième trimestre de 2025
GlobeNewswire
·
July 9, 2025
Les revenus totaux s’élèvent à 17,7 millions de dollars pour le deuxième trimestre de 2025 et à 36,8 millions de dollars pour le premier semestre de l’exercice 2025 Un BAIIA ajusté1 positif a été dégagé pour un cinquième trimestre consécutif Après la …
Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)
GlobeNewswire
·
July 9, 2025
REDWOOD CITY, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), today announced that the abstract titled …
ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference
GlobeNewswire
·
July 9, 2025
WINSTON-SALEM, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members …
Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD)
GlobeNewswire
·
July 9, 2025
GAITHERSBURG, Md., July 09, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled the …
Glucose Health, Inc. Formulations Have Always Been Free of Artificial Colors & Synthetic Dyes—Our Competitors Are Only Playing Catch-Up
GlobeNewswire
·
July 9, 2025
BENTONVILLE, Ark., July 09, 2025 (GLOBE NEWSWIRE) -- Glucose Health, Inc. (OTC: GLUC), the leading innovator in soluble fiber powdered drink mixes for metabolic wellness, proudly affirms that its flagship brands, GlucoDown® and Fiber Up®, have always used …
Aurora Spine Announces Initial Surgeries using its AERO™ Lumbar Fusion System
GlobeNewswire
·
July 9, 2025
CARLSBAD, CALIFORNIA, July 09, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in innovative spine and interventional pain management solutions, today announced initial surgeries …
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861
GlobeNewswire
·
July 9, 2025
NMRA-861 has potential best-in-class pharmacology, which may enable a more favorable therapeutic profile No convulsions observed in pre-clinical studies conducted in multiple species, including rabbits WATERTOWN, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- …
Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4
GlobeNewswire
·
July 9, 2025
NEW YORK, July 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the …
Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis
GlobeNewswire
·
July 9, 2025
Eye drop administration of KB801 designed to enable sustained expression of NGF in the front of the eye Investor call and webcast to be held July 9 at 8:30 am ET to discuss program and trial design PITTSBURGH, July 09, 2025 (GLOBE NEWSWIRE) -- Krystal …
Tilray Brands to Announce Fourth Quarter and Fiscal Year 2025 Financial Results on July 28, 2025
GlobeNewswire
·
July 9, 2025
NEW YORK and LEAMINGTON, Ontario, July 09, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness …
InspireMD Announces U.S. Commercial Launch of CGuard® Prime Carotid Stent System for the Prevention of Stroke
GlobeNewswire
·
July 9, 2025
MIAMI, July 09, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Prime carotid stent system for the prevention of stroke, today announced the official commercial launch of the CGuard Prime carotid stent system in the U.S., …
Nusano Achieves Key Technology Milestone Enabling Simultaneous Production of Multiple Radioisotopes
GlobeNewswire
·
July 9, 2025
Pairing of custom-built klystrons and fast-pulse modulators enable production of up to 12 radioisotopes in a single run Power and efficiency of Nusano system to surpass existing commercial methodologies Beam time reservations and isotope supply agreements …
Arvinas Announces Retirement of Chief Executive Officer and Succession Plan
GlobeNewswire
·
July 9, 2025
– John Houston, Ph.D., Chairperson, CEO and President at Arvinas, Announces Plans to Retire as CEO Upon Appointment of Successor – – Dr. Houston to Remain Chairperson of Arvinas Board of Directors – – Arvinas Board of Directors to Lead Search for CEO …
BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit
GlobeNewswire
·
July 9, 2025
RESEARCH TRIANGLE PARK, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present new findings from patient-focused research highlighting the burden of current treatments for HAE on …
Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025
GlobeNewswire
·
July 9, 2025
– Company reports sequential quarterly growth of 32.8% over Q1 2025 with a record 13,434 YCANTH® dispensed applicator units in Q2 2025 – – Company reports receipt of $8 million milestone payment from its Japanese development partner, Torii Pharmaceutical, …